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support the assembly and coherent display of distributed 
mechanistic information from the literature to support the 
use of alternative approaches for prediction of toxicity. This 
AOP was developed according to the guidance document 
on developing and assessing AOPs and its supplement, the 
users’ handbook, issued by the Organisation for Economic 
Co-operation and Development.
Keywords Adverse outcome pathway (AOP) · Liver 
fibrosis · Alternatives to animal testing · Risk assessment · 
Systems toxicology
Introduction
Liver fibrosis typically results from repeated-dose toxic 
injury and is an important human health issue associated 
with chemical exposure, which disrupts the normal liver 
architecture, alters organ function and may further develop 
to cirrhosis and liver cancer with considerable mortal-
ity attributable to these end stages (Bataller and Brenner 
2005; Carey and Carey 2010; Lee 2003; Lim and Kim 
2008; Mehta et al. 2014; Ramachandran and Kakar 2009). 
Regardless of the causing stimuli (i.e. toxic, metabolic, 
inflammatory, parasitic, or vascular), chronic hepatic injury 
may lead to liver fibrosis by the same mechanisms (Fried-
man 2003). This pathophysiological response not only 
affects the liver, but is common to many organs and tissues, 
where chronic injury triggers a series of key events (KEs) 
that finally leads to fibrosis. Same factors, as described in 
this work, contribute synergistically to fibrogenesis (Chen 
and Raghunath 2009; Johnson and DiPietro 2013; Kisse-
leva and Brenner 2008; Liedtke et al. 2013; Wynn 2008).
Animal models, especially rodents, are commonly used 
to study cellular and molecular mediators of fibrosis. In 
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addition, human health chemical risk assessment is based 
on whole animal toxicity testing with single chemicals 
of concern (OECD 2013). Ethical considerations and 
international animal welfare rules, as well as the uncer-
tain predictability of animal testing for human adverse 
health effects, represent limiting factors for in vivo test-
ing (O’Brien et al. 2006; Seok et al. 2013). Moreover, due 
to costs and time involved, it is not feasible to use these 
methods for testing all of the chemicals that could affect 
human health (Krewski et al. 2010; OECD 2013). “Toxic-
ity testing in the twenty-first century” aims to understand 
the underlying mechanisms of toxicity, rather than rely on 
direct observations of toxic effects. Sufficiently perturbed 
cellular response pathways can turn into “toxicity path-
ways” that result in adverse health effects (Berg et al. 2011; 
Kavlock et al. 2009; Krewski et al. 2010). In this context, 
the adverse outcome pathway (AOP) conceptual frame-
work was developed as a tool for supporting chemical risk 
assessment based on mechanistic reasoning.
Conceptually, an AOP can be viewed as a sequence of 
events starting with an initial interaction of a stressor with 
a biomolecule in a target cell—termed the molecular ini-
tiating event (MIE)—and progressing through a dependent 
series of intermediate KEs at different levels of biological 
organisation, finally culminating in an adverse outcome 
(AO). AOPs are typically represented sequentially, mov-
ing from one KE to another, as compensatory mechanisms 
and feedback loops are overcome. These KEs are a lim-
ited number of measurable and toxicologically relevant 
molecular occurrences that are essential for progression 
towards the AO. It is important to keep in mind that an AOP 
does not provide a comprehensive molecular description 
of every aspect of the biology involved (the mechanism 
of action), but focuses on the critical steps in the pathway 
(Fig. 1) (Ankley et al. 2010; OECD 2013). The structured 
mechanistic knowledge enables development of integrated 
testing strategies, which rely on using in vitro methods, 
preferably based on human cells or human cell constitu-
ents, that in combination with in silico approaches facilitate 
in vivo predictions of toxicity and chemical risk assessment 
(Berg et al. 2011; Krewski et al. 2010; Vinken 2013).
Since liver fibrosis results from a complex interplay 
between various hepatic cell types, receptors and signalling 
pathways (Cong et al. 2012) elaborate multi-cell models 
for the investigation of toxicological processes in vitro are 
required. Liver slices, hepatic cell lines, and primary hepat-
ocytes are currently the leading models for in vitro liver 
toxicity testing; embryonic or induced pluripotent stem 
cells are being introduced as renewable source of cells. The 
selection of liver models is increasing and novel cell cultur-
ing strategies such as three-dimensional cell culturing sys-
tems and co-cultures with two or more liver cell types are 
being devised. However, these models still lack the ability 
































Fig. 1  A schematic representation of the adverse outcome pathway 
(AOP). An AOP starts with a molecular initiating event in which 
a chemical interacts with a biological target (anchor 1) leading to a 
sequential series of intermediate key events at different levels of bio-
logical organisation to produce an adverse outcome with relevance to 
risk assessment (anchor 2)
1525Arch Toxicol (2017) 91:1523–1543 
1 3
periods (Godoy et al. 2013; LeCluyse et al. 2012; Soldatow 
et al. 2013; Van de Bovenkamp et al. 2007; Westra et al. 
2014).
Here, we describe the AOP developed for liver fibrosis, 
from hepatic injury caused by protein alkylation to the for-
mation of liver fibrosis. It is among the first AOPs that were 
developed according to the guidance document on develop-
ing and assessing AOPs and its supplement, the users’ hand-
book, issued by the Organisation for Economic Co-oper-
ation and Development (OECD). The AOP development 
activity was started in the context of the Safety Evaluation 
Ultimately Replacing Animal Testing (SEURAT-1, http://
www.seurat-1.eu) research project, which aimed at devel-
oping alternative models for safety assessment based on 
mechanistic knowledge. To this aim, AOPs for chronic liver 
injury were developed in order to facilitate design of stud-
ies for predicting selected types of repeated-dose toxicity 
(Landesmann et al. 2012; Vinken 2015; Vinken et al. 2013). 
Along with the ongoing evolution of the AOP concept, this 
pathway description has been revised, extended, and modi-
fied within the AOP Wiki (https://aopkb.org/aopwiki/index.
php/Main_Page), a central AOP development platform and 
repository within the OECD AOP Development Work Plan, 
managed by the Extended Advisory Group on Molecu-
lar Screening and Toxicogenomics (http://www.oecd.org/
chemicalsafety/testing/adverse-outcome-pathways-molecu-
lar-screening-and-toxicogenomics.htm). The AOP Wiki is 
one component of the AOP Knowledge Base (https://aopkb.
org) that has been created to enable the scientific commu-
nity, in one central location, to share, develop, and discuss 
their AOP-related knowledge.
Basic principles of AOP development
Building an AOP requires describing a sequence of 
events from a MIE to an AO, while establishing causal 
links between individual KEs. By definition, AOPs 
are not chemical-specific and the pathway description 
should be independent from any specific chemical ini-
tiator (Villeneuve et al. 2014). Nevertheless, in the con-
text of a particular AO, experimental data derived from 
exposure to prototypic chemicals are useful for under-
standing the patterns of biological response. Therefore, 
an AOP development process starts by identifying the 
compounds that have been clinically proven to be induc-
ing the particular adversity of interest. Development of 
the AOP described here was based on two SEURAT-1 
reference chemicals for liver fibrosis, namely carbon 
tetrachloride (CCl4) and allyl alcohol (Jennings et al. 
2014), with their common MIE being protein alkylation 
(covalent protein binding reaction). By selecting first the 
AO followed by progressively tracing down molecular 
response to lower levels of biological organisation, in 
order to connect that outcome with a specific molecu-
lar initiating event, we applied a top-down strategy for 
AOP development. Understanding normal physiological 
processes is the basis for describing the perturbations 
that occur following chemical exposure. KEs, defined as 
changes in biological state, which have to be both meas-
urable and essential for the specific AO, were analysed 
according to different levels of biological organisa-
tion. However, the choice of the relevant level of detail 
in AOP description is crucial. Indeed, too many details 
might distract from understanding the main pathway 
while being too concise holds the risk of overlooking 
relevant processes. Other than the KEs, key event rela-
tionships (KER) constitute a major feature added to the 
initial AOP reporting format. A KER is a scientifically 
based relationship that defines the connection between 
two KEs, by identifying one as an upstream and the 
other one as a downstream event. As such, it facilitates 
inference or extrapolation of the state of the downstream 
KE from the known, measured, or predicted state of the 
upstream KE (Villeneuve et al. 2014).
AOPs are simplified pragmatic constructs, defined as 
linear, non-branching, and directed sequences of KEs, 
connecting a single MIE to an AO. The challenge lies in 
finding an acceptable linear graphical AOP representa-
tion (Fig. 2) in spite of the various existing feed-back and 
feed-forward loops and inter-relationships between KEs 
(Fig. 3). Linear AOPs are at the basis of the weight of 
evidence (WoE) evaluation (Villeneuve et al. 2014), done 
according to Bradford Hill considerations (Meek et al. 
2014) and following the AOP Handbook (OECD 2014). 
The overall assessment of an AOP is best supported by 
thorough descriptions of KEs and their interrelationships 
(KERs), also demonstrating essentiality, biological plau-
sibility, empirical support, and consistency of supporting 
data. Essentiality of KEs is demonstrated by studies in 
which blocking a KE prevents the occurrence of a further 
downstream KEs and ultimately the AO. Table 1 shows the 
overall assessment of the level of confidence in the overall 
AOP based on essentiality of KEs and biological plausibil-
ity, as well as empirical support for KERs. We present the 
AOP for liver fibrosis following the temporal occurrence 
of the individual AOP components.  
MIE: protein alkylation
The initial chemical–biological interaction of this AOP 
for liver fibrosis is protein alkylation, which is the addi-
tion of an alkyl group (i.e. derived from an alkane follow-
ing removal of one hydrogen atom) to a protein amino 
acid. Alkylating agents are highly reactive chemicals that 
1526 Arch Toxicol (2017) 91:1523–1543
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introduce alkyl radicals into biologically active molecules 
and as a consequence can impede or alter their biological 
function (Liebler 2008; Russmann et al. 2009). Covalent 
protein alkylation by reactive electrophiles was identified 
as a major triggering event in chemical toxicity more than 
40 years ago (Codreanu et al. 2014; Kehrer and Biswal 
2000).
KER between protein alkylation and hepatocyte  
injury/death
Even though protein alkylation is a generic process having 
an impact on multiple physiological processes in the cell, 
there is experimental evidence that covalent protein alkyla-
tion does lead to cell injury (Bauman et al. 2009; Thomp-
son and Burcham 2008). Alkylated proteins can disturb the 
cellular redox balance in exposed cells by interacting with 
glutathione, which leads to a disruption of a plethora of 
biochemical pathways and intracellular stress that, depend-
ing on the extent of mitochondrial involvement, can lead 
to apoptotic or necrotic cell death (Codreanu et al. 2014; 
Kaplowitz 2002; Tanel and Averill-Bates 2007). Indeed, 
allyl alcohol/acrolein is considered a mitochondrial toxin 
that leads to cell death (Moghe et al. 2015). Whether apop-
tosis or necrosis ensues after acrolein exposure appears to 
be related to dose and cell type. In regards to activation of 
caspases as part of the mitochondrial death pathway, it was 
shown that apoptosis in human cells is caspase-dependent, 
as demonstrated in human neuroblastoma cells (Dong et al. 
2013) and in A549 lung cells (Roy et al. 2009). It was sug-
gested that the activation of certain caspases may arise 
from a partial inhibition of their active site cysteine resi-
due through direct alkylation by acrolein (Kern and Kehrer 
2002). Furthermore, using biotin hydrazide labelling, it was 
shown that NF-κB RelA and p50, as well as JNK2, were 
revealed as direct targets for alkylation by acrolein, affect-
ing the GSH depletion. Mass spectrometry analysis of acr-
olein-modified recombinant JNK2 indicated adduction to 
Cys(41) and Cys(177), putative important sites involved in 
mitogen-activated protein kinase (MAPK) kinase (MEK) 
binding and JNK2 phosphorylation (Hristova et al. 2012). 
In complimentary work, exposure of cultured hepatocytes 
to acrolein led to a sustained activation of ERK1/2, JNK, 
and p38, which was associated with ER and mitochondrial 
stress and apoptosis. The cytotoxic effects of acrolein were 
decreased by JNK inhibitor, suggesting that kinase activa-
tion may be linked to cell death and liver injury (Moham-
mad et al. 2012). Finally, lipid peroxidation accompanied 
by oxidative stress and collapse of mitochondrial mem-
brane potential can as well trigger apoptotic cell death 
(Fig. 3) (Kehrer and Biswal 2000; Liebler 2008; Manibu-
san et al. 2007).
KE: hepatocyte injury/death
Chemicals and their metabolites can exert their effects 
either directly on cellular macromolecules (i.e. proteins, 
lipids and DNA) in mitochondria, cytoskeletal components, 
endoplasmic reticulum and nucleus, or indirectly through 
activation or inhibition of signalling cascades and transcrip-




























Fig. 2  Graphic representation of the adverse outcome pathway from 
protein alkylation to liver fibrosis. The molecular initiating event 
(MIE) is protein alkylation, leading to structural and functional cell 
injury and cell death, the first key event (KE). Injured and apoptotic 
hepatocytes activate Kupffer cells, the next KE along the pathway. 
Activated KCs are the main source of TGF-β1, the most potent pro-
fibrogenic cytokine. TGF-β1 expression causes the next KE, stellate 
cell activation, which leads to progressive collagen accumulation that 
together with changes in extracellular matrix (ECM) composition 
signifies the KE on tissue level. Collagen bands progress further to 
bridging fibrosis, finally affecting the whole organ. Full arrows rep-
resent direct KERs that link two adjacent KEs. The dotted line rep-
resents an indirect KER that bridges some of the KEs in the pathway
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The outcome may be either triggering of necrotic or apop-
totic processes or sensitisation for the action of cytokines 
(Kaplowitz 2002; Malhi et al. 2010; Orrenius et al. 2011). 
Today, hepatocyte injury is considered as essential for trig-
gering fibrogenesis with hepatocellular apoptosis being 
increasingly viewed as a nexus between liver injury and 
fibrosis (Johnson and DiPietro 2013; Canbay et al. 2002, 
2004a, b; Lotersztajn et al. 2005). Pharmacological inhibi-
tion of liver cell apoptosis attenuates liver injury and fibro-
sis suggesting a critical role for hepatocyte apoptosis in 
the initiation of hepatic stellate cell activation and hepatic 
fibrogenesis (Canbay et al. 2004a, b).
KER between hepatocyte injury/death and Kupffer cell 
(KC) activation
Damaged hepatocytes can trigger KC activation via diverse 
molecular pathways. They release reactive oxygen spe-
cies (ROS), cytokines, including transforming growth 
factor beta 1 (TGF-β1) and tumor necrosis factor alpha 
(TNF-α), and chemokines which all contribute to oxida-
tive stress, inflammatory signalling and finally activation 
of KCs (Orrenius et al. 2011). ROS generation in hepato-
cytes results from oxidative metabolism by NADH oxi-

































































































Fig. 3  Network of molecular events triggered during development 
of liver fibrosis. Molecular mechanisms, feed-back, and feed-forward 
loops as well as inter-relationships between individual key events are 
presented. The central line of events, marked by thick black frames, 
represents the developed AOP, as shown in Fig. 2. Violet boxes corre-
spond to MIE and AO, blue boxes to molecular processes, and green 
boxes to various cell types involved in fibrogenesis. Orange ovals 
represent molecular mediators. α-SMA alpha-smooth muscle actin, 
CTGF connective tissue growth factor, DAMPs damage-associated 
molecular patterns, FasL Fas Ligand, GM-CSF granulocyte mac-
rophage colony-stimulating factor, HNE-4 hydroxynonenal, IFNγ 
interferon gamma, iNOS nitric oxide synthase, MAPK mitogen-acti-
vated protein kinases, MCP-1 monocyte chemoattractant protein-1, 
MMPs metalloproteinases, N2O3 peroxinitrite, NF-κB nuclear factor 
kappaB, NO nitric oxide, NOX NADH oxidase, P450 cytochrome 
P450, PDGF platelet-derived growth factor, PPARγ peroxisome 
proliferator-activated receptor-gamma, ROS reactive oxygen spe-
cies, CSFs colony-stimulating factors, TGF-β1 Transforming growth 
factor beta1, TIMP-1 tissue inhibitor of metalloproteinases-1, TNFα 
tumor necrosis factor alpha, TLRs toll-like receptors, TRAIL TNF-
related apoptosis-inducing ligand, and VEGF vascular endothelial 
growth factor (colour figure online)
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as through lipid peroxidation. Damaged liver cells also 
trigger a sterile inflammatory response with activation of 
innate immune cells through release of damage-associated 
molecular patterns (DAMPs), which activate KCs through 
toll-like receptors (TLRs) and recruit activated neutro-
phils and monocytes into the liver. Central to this inflam-
matory response is the promotion of ROS formation by 
these phagocytes (Jaeschke 2011; Guo and Friedman 
2010; Ramaiah and Jaeschke 2007). In addition, apoptotic 
hepatocytes can undergo genomic DNA fragmentation and 
formation of apoptotic bodies. These apoptotic bodies are 
consecutively engulfed by KCs thereby causing their acti-
vation (Canbay et al. 2003a, b, 2004a, b; Liu et al. 2010). 
The increased phagocytic activity strongly up-regulates 
NOX expression in KCs, a superoxide producing enzyme 
with pro-fibrogenic activity, as well as nitric oxide synthase 
(iNOS) mRNA levels, followed by a consequent harm-
ful reaction between ROS and nitricoxide (NO) that leads 
to generation of cytotoxic peroxinitrite (N2O3) (Paik et al. 
2014). ROS and/or diffusible aldehydes are also derived 
from liver sinusoidal endothelial cells (LSECs) which 
are additional initial triggers of KC activation (Poli 2000) 
(Fig. 3). Experiments on cells of the macrophage lineage 
showed significant aldehyde-induced stimulation of pro-
tein kinase C activity, an enzyme involved in several signal 
transduction pathways. Furthermore, aldehydic products of 
lipid peroxidation, such as 4-hydroxynonenal (HNE), were 
demonstrated to up-regulate TGF-β1 expression and syn-
thesis in isolated rat KCs (Luckey and Petersen 2001).
Complete understanding of the hepatocyte–KC interac-
tion and of its consequences for both normal and toxicant-
driven liver responses still remains a challenge. KC acti-
vation followed by cytokine release is associated in some 
cases with evident liver damage, whereas in other cases this 
event is unrelated to liver damage or may be even protec-
tive. Apparently, the impact is dependent on the extent of 
KC activation, whereby excessive or prolonged release of 
KC mediators can switch from an initially protective mech-
anism to a damaging inflammatory response. Evidence 
suggests that low levels of cytokine release from KCs con-
stitute a survival signal that protects hepatocytes from cell 
death and in some cases, stimulates proliferation (Kisseleva 
and Brenner 2008; Kolios et al. 2006; Malhi et al. 2010). 
Therefore, this KER is biologically plausible, but empiri-
cal evidence is currently rather limited. Unfortunately, 
activation of KC does not result in morphological changes, 
so staining techniques cannot be employed. A more reli-
able marker is cytokine release, even though it has to be 
evaluated in view of KCs’ propensity to activate sponta-
neously in in vitro conditions. Indeed, addition of KCs to 
hepatocytes in vitro does mimic drug-induced inflamma-
tory responses in vivo (Tukov et al. 2006). Nevertheless, it 
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apoptotic bodies stimulated KCs to generate cytokines 
(Canbay et al. 2004a, b; Luckey and Petersen 2001). Take-
hara et al. (2004) showed that persistent apoptosis of paren-
chymal cells led to increased TGF-β production and con-
secutive development of liver fibrosis in vivo, as well as 
increased TGF-β expression by macrophages in vitro.
KER between hepatocyte injury/death and hepatic 
stellate cell (HSC) activation
In addition to KC activation, damaged hepatocytes can 
also lead to activation of HSCs though the release of ROS, 
cytokines, and chemokines. Engulfment of apoptotic bod-
ies from hepatocytes can result in activation and induc-
tion of NOX expression in HSCs (Paik et al. 2014; Zhan 
et al. 2006). DNA from apoptotic hepatocytes induces TL 
9—dependent changes of HSCs that are consistent with 
late stages of HSC differentiation (activation), with up-
regulation of collagen production and inhibition of plate-
let-derived growth factor (PDGF)-mediated chemotaxis to 
retain HSCs at sites of cellular apoptosis. The release of 
latent TGF-β complex into the microenvironment by dam-
aged hepatocytes is likely to be one of the first signals for 
adjacent HSCs leading to their activation (Canbay et al. 
2004a, b; Friedman 2008; Kisseleva and Brenner 2008; Lee 
and Friedman 2011; Li et al. 2008; Malhi et al. 2010; Roth 
et al. 1998) (Fig. 3).
This KER describes the linkage between two non-
adjacent KEs and is, therefore, called indirect. It is bio-
logically plausible and there is experimental evidence to 
demonstrate a mechanistic link between hepatocyte apop-
tosis and fibrogenesis. Markers of HSC activation were 
significantly reduced after pharmacological inhibition of 
liver cell apoptosis using a pan-caspase inhibitor (Canbay 
et al. 2002, 2004a, b). Furthermore, it was observed that 
hepatocyte-HSC co-culturing increased the secretion of 
pro-inflammatory cytokines (Coulouarn et al. 2012). Fluo-
rescently labelled hepatocyte apoptotic bodies were added 
to cultures of primary and immortalised human HSCs that 
readily engulfed apoptotic bodies in a time-dependent man-
ner, followed by an increase in alpha-smooth muscle actin 
(α-SMA) (primary cells), TGF-β1, and collagen alpha1(I) 
mRNA (primary and immortalised cells). It was shown 
that pro-fibrogenic response was dependent upon apoptotic 
body engulfment, since nocodazole, a microtubule-inhib-
iting agent, blocked both the engulfment and the increase 
of TGF-β1 and collagen alpha1(I) mRNA (Canbay et al. 
2003a, b).
Damaged hepatocytes also influence LSECs, which as 
an integral part of the hepatic reticulo-endothelial system 
have a role in HSC activation. LSECs are morphologically 
identified by their fenestrations, which are transcytoplas-
mic canals arranged in sieve plates. In healthy liver, this 
phenotype is maintained by hepatocytes and HSCs that 
release vascular endothelial growth factor (VEGF). Dif-
ferentiated (i.e. fenestrated) LSECs prevent HSC activa-
tion and promote reversal of activated HSC to quiescence. 
However, upon liver injury, they lose this role. Preclinical 
studies have demonstrated that LSECs undergo defenestra-
tion as an early event that not only precedes liver fibrosis, 
but on its own may also promote it, proving that changes in 
LSEC differentiation might be an integral part in the devel-
opment of fibrosis. In addition, during fibrogenesis, LSECs 
become highly pro-inflammatory and secrete an array of 
cytokines and chemokines (Connolly et al. 2010; DeLeve 
2013; Ding et al. 2014; Xie et al. 2012, 2013).
KE–KC activation and macrophage recruitment
KCs constitute 80–90 % of the tissue macrophages in the 
liver reticulo-endothelial system and account for approxi-
mately 15 % of the total liver cell population (Bouwens 
et al. 1986; Kolios et al. 2006). When activated, they are 
involved in pathogenesis of chemical-induced liver injury 
through the release of inflammatory mediators includ-
ing cytokines, chemokines, lysosomal, and proteolytic 
enzymes and are a main source of TGF-β1 (Luckey and 
Petersen 2001; Winwood and Arthur 1993). In addition, 
latent TGF-β1 can be activated by KC-secreted matrix met-
alloproteinase 9 (MMP-9) (Friedman 2002; Kisseleva and 
Brenner 2008). Activated KCs also contribute to oxidative 
stress, which activates a variety of transcription factors, like 
nuclear factor κB (NF-κB) and peroxisome proliferator-
activated receptor-gamma (PPAR-γ), leading to increased 
gene expression and production of growth factors, inflam-
matory cytokines, and chemokines. KCs express mitogens 
and chemoattractants for HSCs, such as TNF-α, interleu-
kin-1 (IL-1), and monocyte chemoattractant protein-1 
(MCP-1). They also induce the expression of PDGF recep-
tors on HSCs, which enhances cell proliferation (Kolios 
et al. 2006). In addition to being pro-inflammatory mol-
ecules, expressed TNF-α, TNF-related apoptosis-inducing 
ligand (TRAIL), and Fas Ligand (FasL) are also capable 
of inducing death receptor-mediated apoptosis in hepato-
cytes (Kershenobich Stalnikowitz and Weissbrod 2003; 
Roberts et al. 2007). Under oxidative stress, macrophages 
are further activated leading to an enhanced inflamma-
tory response that further activates KCs though cytokines 
[interferon gamma (IFNγ), granulocyte macrophage 
colony-stimulating factor (GM-CSF), TNF-α], bacterial 
lipopolysaccharides, extracellular matrix proteins, and 
other chemical mediators (Kershenobich Stalnikowitz and 
Weissbrod 2003).
Besides KCs, which are the resident hepatic mac-
rophages, infiltrating bone marrow-derived macrophages, 
1532 Arch Toxicol (2017) 91:1523–1543
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originating from circulating monocytes, are recruited to 
the injured liver via chemokine signals. KCs appear essen-
tial for sensing tissue injury and initiating inflammatory 
responses, while infiltrating Ly-6C+ monocyte-derived 
macrophages are more linked to chronic inflammation and 
fibrogenesis (Tacke and Zimmermann 2014). The relevance 
of KCs during chronic hepatic injury was demonstrated by 
blocking the infiltration of additional inflammatory mono-
cytes via pharmacological inhibition of the chemokine 
CCL2 (Baeck et al. 2012). KC activation and macrophage 
recruitment are two separate events, both indispensable for 
fibrogenesis. Since they occur in parallel, they can be sum-
marised as one KE (Pellicoro et al. 2014).
Probably there is a threshold for KC activation above 
which liver damage is induced. Pretreatment with gado-
linium chloride, which inhibits KC function, resulted in 
reduced hepatocyte and LSEC injury, decreased number 
of macrophages in hepatic lesions and inhibited TGF-β1 
mRNA expression in macrophages (Andres et al. 2003; 
Ide et al. 2005). Experimental inhibition of KC function or 
their depletion seemed to protect against chemical-induced 
liver injury, which supports the essentiality of this KE (Lot-
ersztajn et al. 2005; Schumann et al. 2000).
KER between KC activation and TGF‑β1 expression
Following activation, KCs become the main source of 
TGF-β1, the most potent pro-fibrogenic cytokine, as well 
as of inflammatory mediators and ROS (Bataller and Bren-
ner 2005; Brenner 2009; Guo and Friedman 2007; Kirkham 
2007; Kolios et al. 2006; Lee and Friedman 2011). The 
experimental support for this KER came already in 1990 
when it was demonstrated that KCs isolated from alco-
hol-induced fibrotic rat livers express and release TGF-
β1, which was associated with KC-conditioned medium-
induced stimulation of collagen formation by HSCs 
(Matsuoka and Tsukamoto 1990). Further confirmation 
came from observation that freshly isolated KCs have an 
increased mRNA expression of three acute phase cytokines 
(i.e. TNF-α, IL-6, and TGF-β) (Kamimura and Tsukamoto 
1995) and that accumulated CD11b1 macrophages are 
critical for activating HSCs via expression of TGF-β1 (Chu 
et al. 2013).
KE–TGF‑β1 expression
TGF-β1 is a polypeptide member of the TGF-β superfam-
ily of cytokines. TGF-β is synthezised as a non-active pro-
form that forms a complex with both latency-associated 
protein (LAP) and latent TGF-β binding protein (LTBP) 
and undergoes proteolytic cleavage by the endopepti-
dase furin to generate the mature TGF-β dimer. Three 
TGF-β isoforms (i.e. β1, β2 and β3) have been identified, 
but only TGF-β1 was linked to liver fibrogenesis and is 
the most potent fibrogenic factor for HSCs (Gressner and 
Weiskirchen 2006). It plays a central role in fibrogenesis, 
mediating crosstalk between parenchymal, inflammatory, 
and collagen expressing cells. TGF-β1 is released by acti-
vated KCs, LSECs, and platelets. After activation HSCs 
themselves express TGF-β1. Hepatocytes do not produce 
TGF-β1, but are implicated in intracellular activation of 
latent TGF-β1. TGF-β1 can also induce its own mRNA 
expression to sustain high levels in local sites of liver injury 
(Kisseleva and Brenner 2008). TGF-β1 activates HSCs, 
stimulates extracellular matrix (ECM) synthesis, and sup-
presses its degradation. It stimulates collagen transcription 
in HSCs and the expression of connective tissue growth 
factor (CTGF), a pro-fibrogenic peptide that stimulates 
the synthesis of collagen type I and fibronectin; further it 
induces the expression of tissue inhibitor of metallopro-
teinases-1 (TIMP-1), an inhibitor of the collagen cleav-
ing enzymes MMP-8 and MMP-13. TGF-β1 increases the 
α1(I) collagen mRNA half-life, mediated by increasing sta-
bility of α1(I) collagen mRNA through mitogen-activated 
protein kinases (MAPK) (Li et al. 2008). TGF-β1 further 
recruits inflammatory cells, portal fibroblasts, and circu-
lating myofibroblasts to the injured liver and triggers the 
apoptosis of hepatocytes (Kershenobich Stalnikowitz and 
Weissbrod 2003; Leask and Abraham 2004; Parsons et al. 
2007; Williams et al. 2000). TGF-β1 is an established 
mediator and regulator of epithelial–mesenchymal-tran-
sition (EMT—the process of transition of differentiated 
epithelial cells into mesenchymal cells), which further con-
tributes to the production of ECM. It has been shown that 
TGF-β1 mediates EMT by inducing the transcription fac-
tor snail-1 and tyrosine phosphorylation of Smad2/3 with 
subsequent recruitment of Smad4 (Bataller and Brenner 
2005; Brenner 2009; Gressner et al. 2002; Guo and Fried-
man 2007; Kaimori et al. 2007) (Fig. 3). Strategies aimed 
at disrupting TGF-β1 expression or signalling pathways are 
extensively being investigated since blocking this cytokine 
may not only inhibit ECM production, but also accelerate 
its degradation. Animal experiments using different strate-
gies to block TGF-β1 have demonstrated significant anti-
fibrotic effects. Inhibition of experimental fibrosis can be 
done by anti-TGF-β treatments with neutralising antibod-
ies or soluble TbRs (TGF-β receptors) (Cheng et al. 2009; 
Liu et al. 2006; Lotersztajn et al. 2005; Qi et al. 1999; Tang 
et al. 2012).
KER between TGF‑β1 expression and HSC activation
TGF-β1 represents the most potent fibrogenic factor for 
HSCs, facilitating their transdifferentiation from quiescent 
vitamin A—storing cells to proliferative and contractile 
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myofibroblasts. The effects of TGF-β1 are mediated 
by intracellular signalling via Smad proteins. Smads-2 
and 3 are stimulatory, whereas Smad-7 acts inhibitory. 
Smad1/5/8, MAPK, and PI3 kinase drive further signal-
ling pathways in different cell types for TGF-β1 effects 
(Bataller and Brenner 2005; Brenner 2009; Friedman 
2002, 2008; Gressner et al. 2002; Kisseleva and Brenner 
2007; Leask and Abraham 2004; Li et al. 2008; Liu et al. 
2006; Parsons et al. 2007). Providing evidence for TGF-β1-
induced HSC, activation in vitro is impeded by spontaneous 
activation of HSCs under these conditions. Furthermore, at 
the gene expression level, HSCs activated in in vitro condi-
tions do not fully reproduce the changes observed in vivo 
(De Minicis et al. 2007). However, Czaja et al. (1989) did 
prove that treatment of cultured hepatic cells with TGF-β1 
increased type I pro-collagen mRNA levels 13-fold due to 
posttranscriptional gene regulation and in Tan et al. (2013), 
it was shown that short TGF-β1 pulses can exert long-last-
ing effects on fibroblasts.
KE–HSC activation
Multiple cells and cytokines play a role in the regulation 
of HSC activation, which consists of discrete responses—
including proliferation, contractility, fibrogenesis, ECM 
degradation, chemotaxis, and retinoid loss (Friedman 
2010). A two-phase process starts with the initiation phase, 
which is triggered by injured hepatocytes, ROS, and par-
acrine stimulation from neighbouring cell types (i.e. KCs, 
LSECs, and platelets), rendering HSCs sensitised to acti-
vation by up-regulating various receptors. The perpetu-
ation phase refers to maintaining HSCs in an activated 
state, which is a dynamic process, including the secretion 
of autocrine and paracrine growth factors, such as TGF-β1, 
chemokines, and the up-regulation of collagen synthesis, 
mainly type I collagen. In response to growth factors, such 
as PDGF and VEGF, HSCs proliferate. Increased contrac-
tility leads to increased resistance to portal venous flow. 
Driven by chemoattractants, HSC accumulates in areas 
of injury. TGF-β1 synthesis promotes activation of neigh-
bouring quiescent HSCs, whereas the release of hepatocyte 
growth factor (HGF) stimulates regeneration of adjacent 
hepatocytes. The release of chemoattractants like monocyte 
chemoattractant protein-1 (MCP-1) and colony-stimulating 
factors (CSFs) amplifies inflammation. Activated HSCs 
(i.e. myofibroblasts) are the primary collagen producing 
cells, the key cellular mediators of fibrosis, and a nexus 
for converging inflammatory pathways leading to fibrosis 
(Bataller and Brenner 2005; Friedman 2002, 2004; Kisse-
leva and Brenner 2007; Lee and Friedman 2011; Li et al. 
2008) (Fig. 3). Experimental inhibition of HSC activation 
prevents fibrosis (Nakamura et al. 2014; Son et al. 2009), 
which led to the development of anti-fibrotic therapeutic 
strategies that include inhibition of HSC proliferation or 
stimulation of HSC apoptosis (Anan et al. 2006; Li et al. 
2008; Lotersztajn et al. 2005).
KER between HSC activation and collagen 
accumulation/changes in ECM composition
Up-regulation of collagen, mainly type I, synthesis fol-
lowing HSC activation is among the most striking molecu-
lar responses of HSCs to injury and is mediated by both 
transcriptional and posttranscriptional mechanisms. The 
half-life of collagen α1(I) mRNA increases 20-fold in acti-
vated HSCs compared to quiescent HSCs (Li et al. 2008). 
Together with decreased matrix degradation (expression 
of degrading MMPs is down-regulated while their inhibi-
tors TIMPs are up-regulated), ECM composition changes 
and further stimulates HSC activation and production of 
TGF-β1. Also, increased mechanical stiffness of the ECM 
activates HSCs through integrin signalling (Benyon and 
Arthur 2001; Lee and Friedman 2011; Milani et al. 1994). 
Monocytes and macrophages are involved in inflamma-
tory actions by producing large amounts of nitric oxide 
(NO) and inflammatory cytokines, such as TNF-α, which 
have a direct stimulatory effect on HSC collagen synthe-
sis. Chronic inflammation, hypoxia, and oxidative stress 
reactivate EMT developmental programmes that converge 
in the activation of NF-κB (Kershenobich Stalnikowitz and 
Weissbrod 2003; Lopez-Novoa and Nieto 2009; Thompson 
et al. 2011). Since it is difficult to stimulate sufficient col-
lagen production and its subsequent incorporation into a 
pericellular matrix in vitro, analytical methods were devel-
oped to measure pro-collagen secreted into culture medium 
or α-SMA expression, a marker of fibroblast activation. In 
primary culture, HSCs from normal liver begin to express 
α-SMA coincident with culture-induced activation (Bren-
ner 2009; Chen and Raghunath 2009; Rockey et al. 1992; 
Yin et al. 2013).
KE: collagen accumulation and changes  
in ECM composition
Irrespective of upstream events that trigger and maintain 
fibrosis, the final product of myofibroblast cellular activ-
ity is the massive deposition of collagen, which results in 
fibrosis (Friedman 2003). The overall amount of collagen 
deposited by fibroblasts is a result of regulated balance 
between collagen synthesis and collagen catabolism. HSCs 
generate fibrosis not only by increasing cell number, but 
also by increasing ECM production per cell. The basement 
membrane-like ECM normally consists of collagens IV and 
VI, which is progressively replaced by collagens I and III 
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as well as cellular fibronectin during fibrogenesis (Gressner 
and Weiskirchen 2006; Kisseleva and Brenner 2008; Lot-
ersztajn et al. 2005). Although multiple ECM components 
are tremendously up-regulated in hepatic fibrosis, type I 
collagen is the most abundant one. These changes in ECM 
composition initiate several positive feedback pathways 
that further amplify fibrosis. Increasing ECM stiffness is 
a stimulus for HSC activation (Lee and Friedman 2011). 
ECM-provoked signals link with other growth factor recep-
tors through integrin-linked kinase and transduce signals to 
the actin cytoskeleton that promote migration and contrac-
tion (via membrane-bound guanosine triphosphate binding 
proteins, in particular Rho67 and Rac). Activation of cellu-
lar matrix MMPs leads to a release of growth factors from 
ECM-bound reservoirs in the extracellular space, which 
further stimulates cellular growth and fibrogenesis (Milani 
et al. 1994).
In addition to a transition of quiescent HSCs into acti-
vated HSCs and then further into contractile myofibro-
blasts, other cells may transdifferentiate into fibrogenic 
myofibroblasts in liver injury. Additional sources of ECM 
include bone marrow, portal fibroblasts, EMT from hepato-
cytes, and cholangiocytes (Henderson and Iredale 2007). 
Therefore, continuing imbalance between the deposition 
and degradation of the extracellular matrix is a prerequisite 
of liver fibrosis and therefore essential for the AO (Bataller 
and Brenner 2005).
KER between collagen accumulation/changes  
in ECM composition and liver fibrosis
There is a smooth transition without a definite threshold 
from ECM accumulation to liver fibrosis, which is char-
acterised by distortion of the normal hepatic architec-
ture through formation of fibrous scars. There is plenty of 
in vivo evidence that ECM accumulation is a prestage of 
liver fibrosis (Bataller and Brenner 2005; Brancatelli et al. 
2009; Lee and Friedman 2011; Pellicoro et al. 2014; Poy-
nard et al. 1997; Rockey and Friedman 2006).
Additional pro‑fibrogenic actors
Couple of other actors could play an important role in 
driving fibrogenesis without being labelled KEs. Chronic 
inflammation and oxidative stress are ongoing processes 
throughout the pathway and mutually interconnected with 
most of the KEs, being contributors to, as well as, conse-
quences of the on-going fibrogenic process (Kershenobich 
Stalnikowitz and Weissbrod 2003; Parola and Robino 2001; 
Sanchez-Valle et al. 2012; Sivakumar and Das 2008). In 
addition, there are some important fibrogenic signalling 
pathways that influence HSC activation and fibrogenesis, 
such as those belonging to adipokine–leptin system, neu-
roendocrine pathways, and renin–angiotensin system.
Oxidative stress
Oxidative stress is reflected in an imbalance between the 
rate of oxidant production and its degradation. It plays a 
crucial role in liver fibrogenesis by inducing hepatocyte 
injury and death, by activating KCs and HSCs and by 
modulating both the expression and the activity of pro-
fibrogenic cytokines (Kirkham 2007; Poli 2000; Singh 
and Czaja 2007) (Fig. 3). Hence, ROS likely contributes 
to both onset and progression of fibrosis, being simultane-
ously a contributor to and a consequence of the observed 
condition (El Rigal et al. 2013; Parola and Robino 2001). 
Oxidative stress-related molecules, including superoxide, 
hydrogen peroxide, hydroxyl radicals, and aldehydic end 
products, may be derived from hepatocytes, as well as from 
activated KCs, other inflammatory cells and HSCs (Kisse-
leva and Brenner 2007; Lee and Friedman 2011; Natarajan 
et al. 2006). Oxidative stress can activate a variety of tran-
scription factors such as NF-κB and PPAR-γ, which may 
further lead to increased gene expression and production of 
growth factors, inflammatory cytokines, and chemokines, 
thus further fuelling inflammation (Parsons et al. 2007; 
Reuter et al. 2010). Antioxidants display anti-fibrogenic 
properties in cell cultures and in experimental animal mod-
els (Lotersztajn et al. 2005). Specifically, PDGF-induced 
increases in collagen deposition and liver fibrosis is mark-
edly reduced by treatment with the anti-oxidant MnTBAP 
chloride, a cell permeable superoxide dismutase (SOD) 
mimetic and peroxynitrite scavenger (El Rigal et al. 2013).
Chronic inflammation
Development of liver fibrosis is also driven by chronic 
inflammation in response to injury affecting all cell types 
involved in the pathogenesis. The fibrogenic cascade is 
maintained by mediators secreted by inflammatory and pro-
fibrogenic cells that stimulate each other in amplifying the 
pathogenic process (Fig. 3). Damaged hepatocytes release 
inflammatory cytokines that activate macrophages (Kupffer 
cells) and stimulate further recruitment of inflammatory 
cells, which produce pro-fibrotic cytokines and chemokines 
that in turn activate fibroblasts (Fujiwara and Kobayashi 
2005). Dead or apoptotic hepatocytes are phagocytosed 
by leukocytes resulting in release of pro-inflammatory 
cytokines (TNF, IL-6 and IL-1β) and recruitment of T cells 
(Bataller and Brenner 2005). Similarly, resident Kupffer 
cells secrete various cytokines and chemokines upon their 
activation (TGFβ, CCL2 and CCL5; Tacke and Zimmer-
mann 2014). However, the central role belongs to activated 
HSCs, of which various functions include direct interaction 
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with different immune cell populations, secretion of pro-
inflammatory cytokines and chemokines (such as CCL2-5, 
CCR5, CCR7), production of NOX enzymes and ROS, as 
well as presenting antigens in the injured liver. All these 
properties allow us to consider stellate cells, central to the 
fibrogenic process, as innate immune cells (Pellicoro et al. 
2014).
Recently, it became evident that also adaptive immune 
cells are involved in fibrogenesis (Xu et al. 2012), and 
moreover, it was suggested that the ratio of anti-fibrotic 
(TH1) and pro-fibrotic (TH2) T helper cells could influence 
the outcome of the fibrotic response, as observed in mouse 
models for fibrosis (Shi et al. 1997). TH2 cells secrete 
IL-13, a pro-fibrogenic mediator, which can promote fibro-
sis either by stimulating TGF-β1 synthesis and activation, 
or independently of TGF-β1, by controlling the relative 
expression of IL-13 receptors on myofibroblasts (Chiara-
monte et al. 1999; Wynn 2004)). On the other hand, TH1 
cells stimulate the production of anti-fibrotic mediators 
IFNγ and IL-12 (Muhanna et al. 2008). Additional T cell 
inflammatory mediators, whose roles in fibrogenesis still 
need to be confirmed, could be TH17 cells that were asso-
ciated with induction of secretion of pro-inflammatory 
cytokines IL-1β, IL-6, TNF, and TGF-β by various cell 
types resident in liver (Korn et al. 2009); regulatory T cells 
(TReg) that have exhibited both anti-fibrogenic (Katz et al. 
2011) and pro-fibrogenic (Langhans et al. 2013) behav-
iour; and cytotoxic T cells (CD8+ T cells) that could serve 
a pro-fibrogenic role (Safadi et al. 2004), even though mice 
deficient in these cells showed no difference in the devel-
opment of liver fibrosis upon CCl4 exposure (Novobrant-
seva et al. 2005). Interestingly, anti-fibrotic activity was 
also attributed to natural killer (NK) cells and γδ T cells 
that induce apoptosis of stellate cells (Hammerich et al. 
2014; Taimr et al. 2003); whereas the natural killer T cells 
(NKT) were shown to promote fibrosis by secreting pro-
fibrotic cytokines IL-4 and IL-13 (Bonecchi et al. 2000). 
In a mouse model of fibrosis, population of dendritic cells 
(DCs) increased significantly stimulating the activity of 
NK cells, T cells, and HSCs (Connolly et al. 2009). The 
complement system, as an innate immune mechanism of 
host defence, plays a role in fibrogenesis via the comple-
ment factor 5 (C5) (Hillebrandt et al. 2005), whose deple-
tion in mice leads to impaired liver regeneration (Mastellos 
et al. 2001). Innate lymphoid cells (nuocytes), neutrophils, 
and mast cells are additional cell types that might play a 
role in fibrogenesis (Franceschini et al. 2007; Harty et al. 
2010; Liang et al. 2013), even though the results are not 
always conclusive (Saito et al. 2003; Sugihara et al. 1999; 
Xu et al. 2004). Importantly, since the majority of find-
ings discussed here comes from rodent models, additional 
research is needed to attribute these functions to human 
counterparts.
Chronic inflammatory response often goes hand in 
hand with tissue destruction and repair. Tissue damage is 
enhanced by activated inflammatory cells, which also rep-
resent a major source of oxidative stress-related molecules 
(Bataller and Brenner 2005; Henderson and Iredale 2007; 
Marra 2002; Parola and Robino 2001). Interestingly, sup-
pression of inflammatory activity by eliminating the aetio-
logical agent, such as a virus, or dampening the immune 
response can halt or even reverse the fibrotic process (Czaja 
2014). Studies examining the role of individual inflamma-
tory cell populations in experimental models provide evi-
dence that the immune system can regulate the progression 
as well as the homeostasis or even regression of liver fibro-
sis (Pellicoro et al. 2014). Most probably, the outcome will 
depend on the aetiology that drives the fibrotic process as 
well as the balance between pro-fibrotic and anti-fibrotic 
cell elements, including populations of pro-inflammatory 
and pro-resolution macrophages, T helper cells, and non-
conventional T cell subsets.
Adipokine–leptin system
Adipokines are secreted mainly by adipose tissue, but also 
by resident and infiltrating macrophages and are increas-
ingly recognised as mediators of fibrogenesis (Fried-
man 2010). Leptin promotes HSC fibrogenesis, enhances 
TIMP-1 expression and acts as a pro-fibrotic agent through 
suppression of PPARγ, an anti-fibrogenic nuclear receptor 
that can reverse HSC activation. The expression of leptin 
receptor is up-regulated during HSC activation; therefore, 
leptin activity is increased through enhanced signalling. 
Downstream effects include increased release of TGF-β1 
from KCs. The counter-regulatory hormone adiponectin is 
reduced in hepatic fibrosis (Lee and Friedman 2011; Lot-
ersztajn et al. 2005).
Neuroendocrine pathways
Upon chronic liver injury, the local neuroendocrine system 
is triggered and activated HSCs express specific receptors, 
most prominently those regulating cannabinoid signal-
ling. Activated HSCs are additionally a key source of the 
endogenous cannabinoid, 2-arachidonylglycerol (2-AG), 
which drives increased (cannabinoid-receptor) CB1 sig-
nalling. Stimulation of the CB1 receptor is pro-fibrogenic, 
whereas the CB2 receptor is anti-fibrotic and hepatoprotec-
tive. Opioid signalling increases proliferation and collagen 
production in HSCs. Serotonin has a pro-fibrotic effect that 
synergises with PDGF signalling. Also thyroid hormones 
enhance activation of HSC (through increased p75 neuro-
trophin receptor (p75NTR) and activation of Rho), thereby 
accelerating the development of liver fibrosis (Friedman 
2010; Lee and Friedman 2011; Lotersztajn et al. 2005).
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Renin–angiotensin system
Angiotensin II (Ang II) is a pro-oxidant and fibrogenic 
cytokine that stimulates DNA synthesis, cell migration, 
procollagen α1(I) mRNA expression, and secretion of 
TGF-β1 and inflammatory cytokines. These fibrogenic 
actions are mediated by NOX (Kisseleva and Brenner 
2007; Lee and Friedman 2011; Lotersztajn et al. 2005).
Overall assessment of the AOP for liver fibrosis
Essentiality, biological plausibility and empirical evidence 
are explained in detail within respective KE and KER chap-
ters and summarised in Table 1. We rated essentiality as 
“high” for all KEs due to the existence of experimental evi-
dence that blocking them would prevent or attenuate, where 
complete blocking is not possible, the next downstream KE 
and therefore the whole AOP. Some evidence arises from 
preclinical research for anti-fibrotic agents, which is mainly 
based on the interference with a KE. In summary, pharma-
cological inhibition of liver cell apoptosis attenuates liver 
injury and fibrosis; experimental inhibition of KC function 
protects against liver injury and inhibits TGF-β1 mRNA 
expression in macrophages; animal experiments using dif-
ferent strategies to block TGF-β1 have demonstrated sig-
nificant anti-fibrotic effects; and experimental inhibition of 
HSC activation prevents fibrosis.
Biological plausibility for the first KER (protein alkyla-
tion—cell injury) was rated as “moderate”, whereas all 
others were rated as “high”, because there is good scien-
tific understanding of these relationships. On the other 
hand, empirical support for KERs was rated as “moder-
ate”, because there is only limited empirical evidence that a 
change in the upstream KE leads to an appropriate change 
in the respective downstream KE, especially in respect to 
dose–response (KEup occurring at lower dose than KEdown), 
temporality (KEup occurring at earlier time point than 
KEdown), and incidence (KEup with higher incidence than 
KEdown). Due to the limited availability of adequate cell 
models, dose–response data on KERs are not available. 
Only in the case of the last KER (collagen accumulation-
liver fibrosis), empirical support was considered as “high” 
due to sufficient amount of empirical and clinical evidence.
Dealing with uncertainties and knowledge gaps
Covalent protein alkylation is a broad, non-specific MIE 
and a feature of many hepatotoxic drugs. However, the 
overall extent of protein binding does not adequately dis-
tinguish toxic from non-toxic effects (Bauman et al. 2009). 
Some chemicals significantly alkylate proteins with-
out causing toxicity, which suggests that only alkylation 
of specific protein subsets contributes to injury. Indeed, 
Codreanu et al. (2014) presented an inventory of proteins 
affected by electrophile-mediated alkylation in intact cells 
and suggested that non-toxic covalent binding largely 
affects cytoskeletal protein components, whereas toxic 
covalent binding induces lethal injury by targeting factors 
involved in protein synthesis and catabolism and possibly 
mitochondrial electron transport. Future studies including 
toxic and non-toxic drugs could test these hypotheses and 
provide a better mechanistic basis for interpreting protein 
alkylation in drug safety evaluation. The identification and 
specification of the targeted biomolecules would allow the 
structural definition of chemical initiators and consecu-
tively the profiling and categorising of chemicals related 
to the initiation of this AOP. Furthermore, it is unknown 
whether there is a threshold for initiating this pathway 
and whether this threshold would relate to the extent of 
alkylation of a single or numerous proteins. DNA alkyla-
tion (methylation) could play a role as well, but for the time 
being there is no data to substantiate this claim.
By definition, an AOP has only one MIE and one final 
AO, which constitute the two anchor points. Any other 
MIE that leads to cell injury and further to liver fibrosis 
via the same downstream KEs would constitutes another 
AOP (OECD 2013). However, different agents that cause 
hepatocyte injury by various MIEs would finally lead to 
fibrosis via the same described downstream KEs. E.g. the 
fibrogenic drug methotrexate binds to the enzyme dihy-
drofolate reductase as first molecular interaction (Jennings 
et al. 2014). Hepatocyte injury, therefore, is an early con-
vergent KE for several AOPs, proving its essentiality for 
fibrogenesis. Still, hepatocyte injury does not inevitably 
lead to fibrosis; there are hepatotoxic chemicals, like aceta-
minophen (http://livertox.nih.gov/Acetaminophen.htm) for 
which liver fibrosis has not been observed. The difference 
in progression to liver fibrosis might lie in various cellular 
responses such as apoptosis, necrosis, transdifferentiation, 
or repair and regeneration. There is increasing evidence for 
apoptosis being a main fibrogenic trigger (Canbay et al. 
2004a, b; Wang et al. 2013). Hepatocyte insult/injury with-
out cell death might already be sufficient to trigger fibro-
sis. Potentially, fibrosis-specific features of cell injury 
could be the amount (quantitative difference) rather than 
the kind (qualitative difference) of cell injury. The rate of 
cell injury/death, i.e. the amount of injury within a certain 
time frame could be another plausible initiating param-
eter, as fibrosis is resulting from chronic injury. Assuming 
hepatocyte injury represents a crucial KE, without which 
fibrosis could not occur via this AOP, a simple investigation 
of in vitro hepatotoxicity could provide relevant informa-
tion for potential fibrosis prediction without the need of a 
highly elaborate cell models. EMT, the process of transi-
tion of differentiated epithelial cells into mesenchymal 
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cells, is an additional contribution to fibrogenesis and could 
be a potential fibrosis-specific marker for hepatocytes expe-
riencing injury. This concept is still controversial and dis-
cussions are on-going (Blachier et al. 2013; Iwaisako et al. 
2012; Kisseleva and Brenner 2011; Liedtke et al. 2013; 
Scholten and Weiskirchen 2011; Wells 2010; Zeisberg et al. 
2007).
Discussion
Liver fibrosis is an important health issue with clear regu-
latory relevance. Progressive hepatic fibrosis, ultimately 
leading to cirrhosis, is a significant contributor to global 
health burden (Lim and Kim 2008). In the European Union, 
0.1 % of the population is affected by cirrhosis, the most 
advanced stage of liver fibrosis with full architectural dis-
turbances (Van Agthoven et al. 2001). Besides the epide-
miological relevance, liver fibrosis also imposes a consider-
able economic burden on society. Indeed, the only curative 
therapy for chronic liver failure is liver transplantation. 
More than 5.500 orthotopic liver transplantations are cur-
rently performed in Europe on a yearly basis, costing up 
to €100.000 the first year and €10.000 yearly thereafter 
(Safadi and Friedman 2002). Therefore, much effort is put 
in research to find therapeutic strategies. Several targets for 
anti-fibrotic agents have been identified—first and fore-
most myofibroblasts, but also fibrogenic cytokines, their 
receptors and signalling pathways (Gressner et al. 2009; 
Gressner and Weiskirchen 2006; Li et al. 2008; Lotersz-
tajn et al. 2005; Schuppan and Kim 2013). Even the inhi-
bition of hepatocyte apoptosis has been considered. These 
approaches are also helpful for the identification of KEs 
and their essentiality for the AO. Unfortunately, none of 
these strategies has proved applicable for clinical inter-
ventions because of their severe adverse effects. Research 
is further complicated by the lack of sensitive and spe-
cific clinical biomarkers to measure fibrosis progression or 
reversal (Friedman 2010).
An alternative approach, which deals with prevention 
rather than with consequences of a diseased state, emerges 
from an AOP concept. It aims at using mechanistic toxi-
cological information in order to devise novel strategies 
for prediction of chemical toxicity. This AOP description 
is among the first AOPs that have been developed accord-
ing to the OECD guidelines; it has been repeatedly revised 
along with the evolving practice and guidance in AOP 
development based on increasing experience. It is a plau-
sible qualitative description of the association between AO 
and MIE across different levels of biological organisation, 
based on reviews and published data from in vivo, in vitro 
data, also including available data from clinical observa-
tions. The collection of mechanistic data turned out to be 
rather challenging. Animal studies are mainly focused on 
the AO (apical endpoint) and rarely describe mechanistic 
sequences in detail. Single cell cultures of various liver 
cell types allow studying the individual cell responses to 
injury and provide the opportunity to understand the roles 
that different liver cell types play in fibrogenic processes. 
Several co-culture models allow the investigation of inter-
actions between some individual actors in vitro. But in 
general, these studies were not designed to investigate 
the linkages between various actors and on the whole it is 
rather difficult to find sound empirical evidence to support 
KERs. Due to the pathogenic complexity of liver fibrosis 
with the involvement of many different cell types, there is 
currently no suitable cell model available to challenge the 
reliability and robustness of the AOP and to mimic and fur-
ther explore the sequence of events, especially in quantita-
tive terms. The investigation of quantitative aspects regard-
ing how much change for how long in an upstream KE is 
needed to cause a corresponding change in the next down-
stream KE remains an ambitious goal.
Two actors have been highlighted as essential contribu-
tors to fibrogenesis without being labelled KEs, namely 
chronic inflammation and oxidative stress, which are 
ongoing processes throughout the pathway and mutually 
interconnected with most of the KEs (Kershenobich Stal-
nikowitz and Weissbrod 2003; Parola and Robino 2001; 
Sanchez-Valle et al. 2012; Sivakumar and Das 2008). It has 
been extensively and repeatedly discussed with the AOP 
developer community how to best insert these events into 
the AOP. As they are interrelated with all the other KEs, 
they cannot be put at a certain position inside the path-
way (which, by definition, does not allow any branches or 
bypasses). On the other hand, the removal from the over-
view with their only mention in the individual KEs and 
KERs descriptions does not adequately reflect their impor-
tant role in fibrogenesis. A valid solution has still to be 
found and would also benefit other AOPs, which face simi-
lar problems. For illustrative reasons, Fig. 4 shows these 
interrelationships.
The complex mechanism of fibrogenesis does not only 
affect a single organ, but causes a systemic response which 
equally damages other organs and tissues. The described 
findings in liver fibrosis parallel those in studies of fibro-
genesis in other organs. The same kind of cells and soluble 
factors is involved in all organs (Friedman 2010), e.g. the 
reference compound CCl4 equally affects lymphoid organs, 
lungs, and kidneys (Kisseleva and Brenner 2008). Fibro-
sis may affect lung, kidney, heart and blood vessels, eye, 
skin, pancreas, intestine, brain, and bone marrow. Further-
more, multi-organ fibrosis could occur due to mechanical 
injury or could be drug- or radiation-induced (Liu 2011; 
Wynn 2007, 2008). Since many fibrogenic pathways are 
conserved across tissues, recent findings in liver might be 
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extended to studies of fibrosis in lungs, kidneys, heart, and 
other organs. Identified targets for anti-fibrotic therapeutic 
agents could therefore be valid for all organs that are sus-
ceptible to fibrosis (Sivakumar and Das 2008). Importantly, 
this AOP is not restrictive regarding sex and life-stage.
In addition, findings suggest common conserved path-
ways across different species which initiate and promote 
liver fibrosis. Animal models are used to study fibrogenesis 
and CCl4 intoxication in rats, and mice is probably the most 
widely studied and therefore best characterised model with 
respect to histological, biochemical, cellular, and molecular 
changes associated with the development of fibrosis (Con-
standinou et al. 2005; Iredale 2007).
Conclusion
AOP methodology provides a framework for collecting, 
organising, and evaluating relevant mechanistic informa-
tion on the toxic effects of chemicals, and it is still evolv-
ing with increasing experience from the growing commu-
nity of AOP developers. AOP development is an iterative 
and dynamic process with continuous expansion in accord-
ance with increasing scientific knowledge. The described 
available mechanistic toxicological information serves as 
a knowledge-based repository for the identification of KEs 
along the pathway and might be helpful for the identifica-
tion of novel biomarkers. In vitro methods for measuring 
these KEs, KERs, and biomarkers can be selected or devel-
oped to ultimately support the prediction of chemical tox-
icity. Early (upstream) markers for downstream events can 
be identified to facilitate a testing strategy for chemical risk 
assessment. In addition, the KEs can be used for hazard 
identification and read-across to assess the toxic potential 
of an untested substance. Therefore, AOPs have the poten-
tial to become a powerful tool to support alternative meth-
ods for chemical risk assessment which may be predictive 
of the AO in vivo without the need to actually demonstrate 
the AO. Further AOP development will be facilitated by the 
AOP Wiki, which provides a platform for interdisciplinary 
collaboration between the scientists and the regulators. It 
is essential that many researchers from various disciplines 
like toxicology, biology, chemistry, clinical medicine, and 
computer modelling engage in this activity and contribute 
to AOP development. AOP developers need to share and 
connect their AOPs through common KEs to build AOP 
networks that eventually will better represent the complex 
biological processes and interactions in response to various 
chemical exposures.
This AOP description demonstrates how detailed and 
distributed mechanistic information from the literature can 
be assembled and coherently displayed to support the use 
of alternative data. Together with other AOP descriptions 
leading to chronic liver injury, it provided the basis for the 
design of feasibility studies for predicting selected types of 






























Fig. 4  Graphic representation of the adverse outcome pathway 
describing the linkage between hepatic injury caused by protein 
alkylation and the formation of liver fibrosis, including the display of 
chronic inflammation and oxidative stress, thus illustrating their inter-
relationships with the various KEs
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addition of quantitative data on dose–response relation-
ships, threshold values, and temporal sequences, the acqui-
sition of which is dependent on the availability of suitable 
cell models, would substantially improve the applicability 
of this AOP.
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